None
Quote | Zelda Therapeutics Ltd (OTCMKTS:ZLDAF)
Last: | $0.48 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $0.48 |
High: | $0 |
Low: | $0 |
Volume: | 5 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Zelda Therapeutics Ltd (OTCMKTS:ZLDAF)
Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF) said that it has funding to conduct mid-to-late-stage FDA trials for its cannabinoid-based drug to treat autism spectrum disorder (ASD). The company received $8.6 million in funding from U.S.-based investment firm Cantheon Capital LLC to con...
Zelira Therapeutics Launches ZYRAYDI™ B2B Technology to Create Pharma-grade Cannabis Capsules & Tablets for Global Markets Zelira Therapeutics Launches ZYRAYDI™ B2B Technology to Create Pharma-grade Cannabis Capsules & Tablets for Global Markets PR News...
Message Board Posts | Zelda Therapeutics Ltd (OTCMKTS:ZLDAF)
Subject | By | Source | When |
---|---|---|---|
thanks for posting. | john1311 | investorshub | 05/27/2022 10:10:06 AM |
ZLDAF: effective April 14,2022 a one for 175 | Renee | investorshub | 04/13/2022 1:15:16 PM |
Medical cannabis company Zelira shifts HQ to Plymouth | nonameface13 | investorshub | 03/10/2021 3:09:38 AM |
https://mforum.com.au/cannabis-research-forges-on/ | nonameface13 | investorshub | 03/07/2021 7:07:39 PM |
Why is something like High Tide jumping past | nonameface13 | investorshub | 03/07/2021 7:03:57 PM |
News, Short Squeeze, Breakout and More Instantly...
Zelda Therapeutics Ltd Company Name:
ZLDAF Stock Symbol:
OTCMKTS Market:
Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF) said that it has funding to conduct mid-to-late-stage FDA trials for its cannabinoid-based drug to treat autism spectrum disorder (ASD). The company received $8.6 million in funding from U.S.-based investment firm Cantheon Capital LLC to con...
Zelira Therapeutics Launches ZYRAYDI™ B2B Technology to Create Pharma-grade Cannabis Capsules & Tablets for Global Markets Zelira Therapeutics Launches ZYRAYDI™ B2B Technology to Create Pharma-grade Cannabis Capsules & Tablets for Global Markets PR News...
Zelira Therapeutics Ltd (ASX: ZLD,OTC-QB: ZLDAF ), recieved formal approval from German regulatory authority BfArM to launch in the German medical cannabis market for its new insomnia medication Zenivol. Zenivol is the first clinically validated , pharmaceutic...